Alerta

PYRAZOLYLSULFONAMIDE COMPOUNDS AND THEIR USE IN THERAPY

Absstract of: MX2025002161A

The invention provides pyrazolylsulfonamide compounds, pharmaceutical compositions, their use for inhibiting mucosa-associated lymphoid tissue lymphoma translocation protein 1 (MALT1), and their use in the treatment of a disease or condition, such as a proliferative disorder, inflammatory disorder, or autoimmune disorder.

Methods of treating multiple myeloma

Absstract of: EP4588484A2

The present disclosure provides methods for treating multiple myeloma (such as refractory multiple myeloma or relapsed and refractory multiple myeloma) in an individual who received at least two prior therapies for multiple myeloma. The methods comprise administering to the individual an anti-CD38 antibody, pomalidomide, and dexamethasone. Also provided are methods of improving renal impairment in an individual having multiple myeloma.

COMPOUNDS FOR TREATING CERTAIN LEUKEMIAS

Absstract of: US2025243184A1

Provided herein are compounds, preferably compounds inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, compositions thereof, and methods of their preparation, and methods of inhibiting tyrosine kinase enzymatic activity of a protein selected from Abelson protein (ABL1), Abelson-related protein (ABL2), or a chimeric protein BCR-ABL1, and methods for treating diseases wherein modulation of BCR-ABL1 activity prevents, inhibits, or ameliorates the pathology and/or symptomology of the disease.

ARTICLES OF MANUFACTURE AND METHODS FOR TREATMENT USING ADOPTIVE CELL THERAPY

Nº publicación: AU2025205394A1 31/07/2025

Applicant:

JUNO THERAPEUTICS INC
JUNO THERAPEUTICS, INC

Absstract of: AU2025205394A1

Abstract Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods. Abstract Provided are adoptive cell therapy methods involving the administration of doses of cells for treating disease and conditions, including certain B cell malignancies. The cells generally express recombinant receptors such as chimeric antigen receptors (CARs). In some embodiments, the methods are for treating subjects with non-Hodgkin lymphoma (NHL). In some embodiments, the methods are for treating subjects with relapsed or refractory NHL. Also provided are articles of manufacture and prophylactic treatments in connection with adoptive therapy methods. ul b s t r a c t r o v i d e d a r e a d o p t i v e c e l l t h e r a p y m e t h o d s i n v o l v i n g t h e a d m i n i s t r a t i o n o f d o s e s o f c e l l s u l f o r t r e a t i n g d i s e a s e a n d c o n d i t i o n s , i n c l u d i n g c e r t a i n c e l l m a l i g n a n c i e s h e c e l l s g e n e r a l l y e x p r e s s r e c o m b i n a n